ClinicalTrials.Veeva

Menu

Effectiveness of Convalescent Plasma Therapy in 8 Non-Intubated COVID-19 Patients in Indonesia: A Case Series

M

Maranatha Christian University

Status

Completed

Conditions

Infectious Disease

Treatments

Biological: Convalescent Plasma Therapy

Study type

Observational

Funder types

Other

Identifiers

NCT05046652
0408087106

Details and patient eligibility

About

This is the first Case Studies article highlight factors determine the effectiveness of Convalescent Plasma Therapy (CPT) in Indonesia, accompanied by supporting data and images before and after the patients received the therapy. This Case Studies gives a huge contribution as CPT still on going as multicentre study and apply massively as emergency approved treatment in Indonesia.

Full description

Eight non-intubated Covid-19 patients confirmed by real-time viral RNA PCR tests were included. Four patients had been administered two doses of 200 mL convalescent plasma (CP) and another four patients had been administered one dose of CP with an antibody titer of 1:320. This study has three goals included to detect the improvement of patient clinical and laboratory conditions, safety of CPT, and conversion from positive to negative results after CPT administration. Convalescent plasma applied within two weeks (13 days) from onset of illness and within a week (6.5 days) from the first day of hospital admission for all patients. Improvements in clinical symptoms, laboratory parameters, thorax photo, negative conversion of PCR, and decreased oxygen supplementation occurred within a week after CPT. Patients with two doses of CP tended to have faster recovery than those with one dose of CP. No severe adverse effects were observed in any patient. This is the first case series in Indonesia showing CPT is safe and well tolerated, and early CPT before the patient is intubated could potentially prevent disease progression, increase the recovery rate, and shorten the inpatient days.

Enrollment

8 patients

Sex

All

Volunteers

No Healthy Volunteers

Inclusion criteria

  • COVID-19 patients
  • Severe stage
  • Positive PCR swab

Exclusion criteria

  • Non-COVID-19 patients
  • No Symptoms COVID-19 patients
  • Mild COVID-19 patients

Trial design

8 participants in 2 patient groups

One bag of convalescent plasma therapy
Description:
Four patients had been administered one dose of 200 mL CP with an antibody titer of 1:320.
Treatment:
Biological: Convalescent Plasma Therapy
Two bags of convalescent plasma therapy
Description:
Four patients had been administered two doses of 200 mL CP with an antibody titer of 1:320.
Treatment:
Biological: Convalescent Plasma Therapy

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems